Matinas BioPharma (NYSEAMERICAN:MTNB) Sets New 12-Month High at $4.67

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) reached a new 52-week high on Thursday . The company traded as high as $4.67 and last traded at $4.67, with a volume of 0 shares changing hands. The stock had previously closed at $0.09.

Matinas BioPharma Price Performance

The firm has a market capitalization of $1.17 billion, a PE ratio of -38.88 and a beta of 1.70.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Private Advisor Group LLC increased its position in Matinas BioPharma by 31.1% in the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock valued at $73,000 after acquiring an additional 80,000 shares in the last quarter. Alliance Wealth Management Group bought a new position in Matinas BioPharma in the 2nd quarter worth approximately $299,000. Towercrest Capital Management acquired a new position in Matinas BioPharma during the 2nd quarter worth $299,000. Finally, Highbridge Capital Management LLC bought a new position in Matinas BioPharma in the 2nd quarter valued at $1,685,000. 11.77% of the stock is owned by institutional investors and hedge funds.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.